Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: PLC Systems

This article was originally published in The Gray Sheet

Executive Summary

PLC Systems: Firm's Heart Laser transmyocardial revascularization system likely will need to undergo a second review by FDA's Circulatory System Devices Panel, Robert Rudko, PhD, chairman and chief scientific officer, stated Oct. 27 at the Oppenheimer & Co. conference in New York City. Following the panel's July "not approvable" recommendation, FDA requested additional data to support a February 1997 premarket approval application. The panel called for 12 month follow-up on 200 patients ("The Gray Sheet" Aug. 4, p. 7). PLC Systems has collected the data and is preparing to submit it in November, Rudko said...

You may also be interested in...

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts